ProCE Banner Activity

What’s New Regarding Frontline Immunotherapy Combinations in Advanced NSCLC

Clinical Thought
How do you treat patients with advanced NSCLC in the era of immunotherapy? In this commentary, Dr. Gubens discusses the latest data on frontline combination regimens using immunotherapy for the treatment of advanced NSCLC.

Released: December 30, 2019

Expiration: December 28, 2020

Share

Faculty

Matthew Gubens

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Celgene

Loxo Oncology subsidiary of Eli Lilly

Partners

GRACE

ProCE Banner

Faculty Disclosure

Primary Author

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Matthew Gubens, MD, MS, has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech/Roche, Heron, and Takeda and funds for research support from Celgene, Merck, Novartis, and OncoMed.